Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07512596RecruitingPhase 2
Study of a new antibiotic for hospital pneumonia from resistant bacteria
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
Bengbu, AnhuiAges 18 years+ - NCT07513181RecruitingPhase 2
Testing ATH-063 for Hard-to-Treat Ulcerative Colitis
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
Miami, FloridaAges 18–75 - NCT07507513RecruitingPhase 2
New drug for moderate to severe ulcerative colitis
This study tests a new medication (called 627) for people with moderate to severe ulcerative colitis who haven't responded well to or couldn't tolerate other treatments. The goal is to see if it can safely reduce inflammation and improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT06760221Recruiting
Spotlight on bone cancer: SBRT plus surgery
This trial tests if giving a high dose of focused radiation (SBRT) before surgery can improve outcomes for people with aggressive soft tissue sarcoma in an arm or leg. You may be able to avoid chemotherapy and still have a good result.
Hangzhou, ZhejiangAges 18–80 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07512557Recruiting
Probiotic Safety and Effectiveness Study for Women
This research tests a new probiotic supplement to see if it's safe, easy to take, and works well. You'll take the probiotic for several weeks and answer questions about how you feel and any side effects.
Ottawa, OntarioAges 18–40 - NCT07509645RecruitingPhase 3
Testing a new drug with clot removal for severe back-of-the-brain stroke
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
Huaibei, AnhuiAges 18 years+ - NCT07514169RecruitingPhase 2
New Combination Drug for Older Adults with B-Cell Lymphoma
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
ShanghaiAges 70 years+ - NCT07514637RecruitingPhase 2
Pain relief medication after pancreas surgery
This study tests a new drug called Anricfen (ariceptin) to help reduce pain and speed recovery after pancreas removal surgery. Participants receive injections for three days after surgery to see if the medication safely controls pain better than standard care.
NanjingAges 18–80 - NCT07508605RecruitingPhase 1/Phase 2
CD19/CD20 CAR/TRuC-T cells for lymphoma that returned or didn't respond
This trial tests a new type of immune cell therapy that targets two markers (CD19 and CD20) on your lymphoma cells. It is for people whose lymphoma came back or didn't respond to previous treatments, including CD19 CAR-T therapy.
Shenzhen, GuangdongAges 18–75 - NCT07515040Recruiting
AccuSafe guidewire versus needle for heart rhythm procedure
This trial compares two different tools used during a minimally invasive heart procedure to treat atrial fibrillation (an irregular heartbeat). The study tests whether a newer guidewire tool is safer and works as well as the traditional needle approach.
Nanchang, JiangxiAges 18–75 - NCT06515132Recruiting
Spinal cord stimulation for consciousness after brain injury
This trial tests whether spinal cord stimulation can help people who have been minimally conscious for months after a brain injury. It aims to improve awareness and responsiveness by using mild electrical pulses.
Fuzhou, FujianAges 18–65 - NCT06625957RecruitingPhase 3
NTCB02-1 trial for patients needing IV nutrition
This trial tests an investigational IV nutrition product called NTCB02-1 in patients who need nutrition through a vein (parenteral nutrition) for at least 3 days. It aims to see if it is safe and works well.
Gyeonggi-do, Goyang-siAges 19 years+ - NCT06760260RecruitingEarly Phase 1
FLT3-targeted CAR-T cell therapy for relapsed AML
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
Suzhou, JiangsuAges 18–70 - NCT07499440RecruitingPhase 2
Testing a new medicine, HB-1, for PTSD
This trial tests an experimental medicine, HB-1, as a potential treatment for PTSD. It is a 8-week study to see if the medicine is safe and if it reduces PTSD symptoms. You must have a stable medication routine and be willing to take the study pill daily.
Deakin, Australian Capital TerritoryAges 18–65 - NCT07500090RecruitingPhase 3
Study of HBS-301 for idiopathic hypersomnia
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
Birmingham, AlabamaAges 18 years+ - NCT07499544RecruitingPhase 3
Testing Libevitug for chronic hepatitis D
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
Garden Grove, CaliforniaAges 12–70 - NCT07503886RecruitingPhase 2
Study of an eye drop for dry eye disease
This trial tests a new eye drop called DFL24498 to see if it helps people with dry eye disease. You may qualify if your dry eye is moderate to severe and other treatments haven't worked well for you.
Chandler, ArizonaAges 18 years+ - NCT07501559RecruitingPhase 1/Phase 2
Study of JL15003 for recurrent glioblastoma
This trial is testing a new drug (JL15003) given directly into the brain tumor using a small device called an Ommaya reservoir. It is for people whose glioblastoma has come back despite standard treatments. You will need to have had a polio vaccine booster before starting.
ShanghaiAges 18 years+ - NCT07502443RecruitingPhase 3
Study of ALKS 2680 for narcolepsy type 2
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
Cullman, AlabamaAges 18–70 - NCT07499674RecruitingPhase 3
A lung cancer surgery study to test a special imaging dye
This trial tests a dye called abenacianine (VGT-309) that may help surgeons see cancer more clearly during lung surgery. It looks at whether the dye is safe and effective for identifying cancer in people having surgery to remove a lung lesion or mass.
Duarte, CaliforniaAges 18 years+ - NCT07503379RecruitingPhase 2
Darolutamide, hormone therapy and low-dose docetaxel for metastatic prostate cancer
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.